Table 1. Baseline demographics, disease, and ocular characteristics for treatment-naïve and prior ranibizumab-treated patients with mCNV.

Characteristics	Treatment-naïve, n = 108	Prior ranibizumab-treated, n = 175
Patient demographics
Mean (SD) age, years	57.6 (15.6)	59.0 (14.9)
Gender, %
Male	19.4	34.3
Female	80.6	65.7
Race, %
Caucasian	88.9	86.9
Black	0.9	0
Asian	4.6	9.1
Native American	1.9	0
Other	1.9	4.0
Missing	1.9	0
Ocular characteristics
VA
n	59	119
Mean (SD) VA, ETDRS letters	49.5 (20.51)	58.5 (19.79)
Median time from diagnosis to first treatment (treatment-naïve), to study entry (prior ranibizumab-treated), days	14.5	444

ETDRS, Early treatment diabetic retinopathy study; mCNV, myopic choroidal neovascularization; n, number of patients; SD, standard deviation; VA, visual acuity.